Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How Lunit and CellCarta plan to speed up cancer drug trials with AI-driven pathology
Lunit and CellCarta are bringing AI pathology into clinical trials, reshaping biomarker strategies and accelerating precision oncology worldwide.
What makes Qurient’s CDK7 inhibitor pairing with Synaffix’s exatecan payload a potential game changer?
Synaffix and Qurient team up on a dual-payload ADC using exatecan and CDK7 inhibitor, aiming to reshape targeted cancer therapy and boost Lonza’s platform strategy.
FDA approval of Eli Lilly’s Inluriyo: Can the new oral SERD reshape advanced breast cancer treatment?
FDA clears Eli Lilly’s Inluriyo for ESR1-mutated advanced breast cancer. Explore trial data, stock sentiment, pricing, and future oncology outlook.
ZYN002 misses pivotal Fragile X trial — What does the setback mean for Harmony’s pipeline and stock outlook?
Harmony’s ZYN002 fails key Fragile X trial, sending HRMY stock lower. Find out why placebo effects mattered and what’s next for its pipeline.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.
Sotyktu joins Eliquis in Bristol Myers’ direct-to-patient experiment — Is this the future of pharma distribution?
Bristol Myers Squibb adds Sotyktu to its DTC channel with 86% discount, reshaping drug pricing and patient access. See why this matters for pharma.
Sen-Jam Pharmaceutical and KVK Tech clear final hurdle for SJP-002C, setting the stage for pivotal clinical trials
Sen-Jam Pharmaceutical and KVK Tech finalize CMC deliverables for SJP-002C, positioning the novel immunoregulator for pivotal Phase 2b/3 trials.
AbbVie seeks FDA approval for tavapadon to improve motor control in Parkinson’s disease patients
AbbVie (NYSE: ABBV) files FDA application for tavapadon, a once-daily oral Parkinson’s treatment aiming to improve motor control and expand its neuroscience pipeline.
AstraZeneca just joined the direct-to-consumer drug race — here’s what it means for patients and rivals
AstraZeneca launches AstraZeneca Direct in the U.S. with up to 70% discounts. Explore how this direct-to-consumer model could reshape drug access.
Trump’s 100% tariff on branded pharmaceuticals without U.S. plants shocks global drugmakers
Trump’s 100% tariff on branded drugs without U.S. plants could double costs, disrupt supplies, and reshape global pharma strategies. Read what’s at stake.